Doris Kearns Goodwin on her husband, history, and her ‘unfinished love story’

Firing Line with Margaret Hoover

Historian Doris Kearns Goodwin sits down with Margaret Hoover to discuss “An Unfinished Love Story,” her new book recounting the 1960s from her perspective and that of her late husband, presidential speechwriter Dick Goodwin.

The Pulitzer Prize-winning biographer recalls the genesis of the project and reflects on the difference between writing about her husband and long-dead presidents like Abraham Lincoln and Franklin Roosevelt. She details Dick Goodwin’s work for John F. Kennedy and Lyndon Johnson, including writing Johnson’s address to Congress after the Bloody Sunday march in Selma.

Goodwin also addresses declining trust in government since Johnson’s presidency, which she traces to his handling of the Vietnam War. She discusses her husband’s later work on Al Gore’s 2000 concession speech and how presidential candidates recognized the importance of putting patriotism before partisanship after close elections prior to 2020.

Goodwin considers parallels between the 1850s and today and the prospect that current divisions will lead to another civil war. She also explains why she sees her own love story with America as unfinished and why she believes the country has a long way to go to live up to its ideals.

Support for “Firing Line for Margaret Hoover” is provided by Robert Granieri, Vanessa and Henry Cornell, The Fairweather Foundation, The Tepper Foundation, Peter and Mary Kalikow, The Asness Family Foundation, The Beth and Ravenel Curry Foundation, Kathleen and Andrew McKenna through The McKenna Family Foundation, Charles R. Schwab, The Eric and Wendy Schmidt Fund for Strategic Innovation, Pritzker Military Foundation on behalf of the Pritzker Military Museum and Library, The Rosalind P. Walter Foundation, Damon Button, Craig Newmark Philanthropies, The Marc Haas Foundation, Roger and Susan Hertog, Cheryl Cohen Effron and Blair Effron, and Al and Kathy Hubbard. Corporate funding is provided by Stephens Inc. and Pfizer Inc.